Basic and clinical aspects of GnRH‐agonists in reproduction

review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-07

This paper reviews the physiological basis and clinical strategies for using GnRH agonists, which are increasingly important in treating reproductive failure and improving IVF pregnancy rates, and achieving remission in endometriosis and uterine fibroids.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Within recent years GnRH agonists have gained increasing importance in the treatment of reproductive failure. Their use as a pretreatment for in vitro fertilization increases the pregnancy rate at least under certain conditions. In cases of endometriosis and uterus myomatosus, GnRH agonists achieve high remission rates and may avoid or at least postpone the need for surgical intervention. The physiological basis and current clinical strategies are discussed.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Gonadotropin-Releasing Hormone Reproduction Endometriosis Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Infertility, Female Infertility, Female Leiomyoma Leiomyoma Reproduction Uterine Neoplasms Uterine Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:10.587122+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK